Selective expression of cholesterol metabolism genes in normal CD34+CD38- cells with a heterogeneous expression pattern in AML cells

Experimental Hematology

Volumn 34, Issue 5, 2006, Pages 622-630

  Peeters, Susan D P W M ^a,b   van der Kolk, Dorina M ^a,b   de Haan, Gerald ^d   Bystrykh, Leonid ^d   Kuipers, Folkert ^c   de Vries, Elisabeth G E ^b   Vellenga, Edo ^a  

^a Departments of Hematology   (Netherlands)

^b Medical Oncology ^*

^c Pediatrics

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYL COENZYME A REDUCTASE; ABC TRANSPORTER; ABC TRANSPORTER A1; ABCG1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CD34 SELECTION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

ACUTE DISEASE; ANTIGENS, CD34; ANTIGENS, CD38; ATP-BINDING CASSETTE TRANSPORTERS; BASE SEQUENCE; BONE MARROW; CHOLESTEROL; DNA PRIMERS; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

MURINAE;

EID: 33646486572     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.01.020     Document Type: Article

References (44)

1. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
2. Ailles L.E., Gerhard B., Kawagoe H., and Hogge D.E. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 94 (1999) 1761-1772
3. Rombouts W.J., Martens A.C., and Ploemacher R.E. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia 14 (2000) 889-897
4. Legrand O., Simonin G., Beauchamp-Nicoud A., Zittoun R., and Marie J.P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 94 (1999) 1046-1056
5. van der Kolk D.M., de Vries E.G., van Putten W.J., et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 6 (2000) 3205-3214
6. Leith C.P., Kopecky K.J., Chen I.M., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94 (1999) 1086-1099
7. van der Kolk D.M., de Vries E.G., Koning J.A., van den Berg E., Muller M., and Vellenga E. Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res 4 (1998) 1727-1736
8. van der Kolk D.M., Vellenga E., der Veen A.Y., et al. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. Blood 95 (2000) 3514-3519
9. van der Kolk D.M., de Vries E.G., Noordhoek L., et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 15 (2001) 1544-1553
10. van der Kolk D.M., Vellenga E., Scheffer G.L., et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99 (2002) 3763-3770
11. Müller M. Available from: http://www.nutrigene.4t.com/humanabc.htm; accessed August 2003.
12. Bystrykh L., Weersing E., Dontje B., et al. Uncovering regulatory pathways that affect hematopoietic stem cell function using "genetical genomics.". Nat Genet 37 (2005) 225-232. http://www.webqtl.org accessed June 2001
13. Ivanova N.B., Dimos J.T., Schaniel C., Hackney J.A., Moore K.A., and Lemischka I.R. A stem cell molecular signature. Science 298 (2002) 601-604. Available from: http//www.sciencemag.org/cgi/content/full/1073823/DC1 accessed 2004
14. Mitelman F.L. International System for Human Cytogenetic Nomenclature (ISCN) (1995), S. Karger, Basel, Switzerland
15. Koeffler H.P., and Golde D.W. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science 200 (1978) 1153-1154
16. Knowles B.B., Howe C.C., and Aden D.P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209 (1980) 497-499
17. Langmann T., Mauerer R., Zahn A., et al. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 49 (2003) 230-238
18. Fu X., Menke J.G., Chen Y., et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J BiolChem 276 (2001) 38378-38387
19. Shimomura I., Shimano H., Horton J.D., Goldstein J.L., and Brown M.S. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99 (1997) 838-845
20. Raaijmakers H.G., van den Bosch G., Boezeman J., de Witte T., and Raymakers R.A. Single-cell image analysis to assess ABC-transporter-mediated efflux in highly purified hematopoietic progenitors. Cytometry 49 (2002) 135-142
21. Raaijmakers M.H., van Emst L., de Witte T., Mensink E., and Raymakers R.A. Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction. Exp Hematol 30 (2002) 481-487
22. Wang N., Lan D., Chen W., Matsuura F., and Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 101 (2004) 9774-9779
23. Wang N., Silver D.L., Costet P., and Tall A.R. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 275 (2000) 33053-33058
24. Oram J.F., Lawn R.M., Garvin M.R., and Wade D.P. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 275 (2000) 34508-34511
25. Scharenberg C.W., Harkey M.A., and Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99 (2002) 507-512
26. Zhou S., Schuetz J.D., Bunting K.D., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7 (2001) 1028-1034
27. Bunting K.D., Zhou S., Lu T., and Sorrentino B.P. Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. Blood 96 (2000) 902-909
28. Lee M.H., Lu K., Hazard S., et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 27 (2001) 79-83
29. McNeish J., Aiello R.J., Guyot D., et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci U S A 97 (2000) 4245-4250
30. Schmitz G., and Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim Biophys Acta 1735 (2005) 1-19
31. Wagner B.L., Valledor A.F., Shao G., et al. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol Cell Biol 23 (2003) 5780-5789
32. Brown M.S., and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (1997) 331-340
33. Tatidis L., Gruber A., and Vitols S. Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia. J Lipid Res 38 (1997) 2436-2445
34. Kaneko E., Matsuda M., Yamada Y., Tachibana Y., Shimomura I., and Makishima M. Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem 278 (2003) 36091-36098
35. Groen A.K., Oude Elferink R.P., Verkade H.J., and Kuipers F. The ins and outs of reverse cholesterol transport. Ann Med 36 (2004) 135-145
36. Wong J., Quinn C.M., and Brown A.J. Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol 24 (2004) 2365-2371
37. Li H.Y., Appelbaum F.R., Willman C.L., Zager R.A., and Banker D.E. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101 (2003) 3628-3634
38. Banker D.E., Mayer S.J., Li H.Y., Willman C.L., Appelbaum F.R., and Zager R.A. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 104 (2004) 1816-1824
39. Beck S., Kelly A., Radley E., Khurshid F., Alderton R.P., and Trowsdale J. DNA sequence analysis of 66 kb of the human MHC class II region encoding a cluster of genes for antigen processing. J Mol Biol 228 (1992) 433-441
40. Advani R., Saba H.I., Tallman M.S., et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93 (1999) 787-795
41. Greenberg P.L., Lee S.J., Advani R., et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22 (2004) 1078-1086
42. van der Holt B., Lowenberg B., Burnett A.K., et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106 (2005) 2646-2654
43. Hope K.J., Jin L., and Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5 (2004) 738-743
44. + subpopulations. Blood 86 (1995) 2906-2912